Anumana
- Company typePrivate
- Founded2021
- HeadquartersCambridge, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
Anumana firmographics
Firmographics- Name
- Anumana
- Legal name
- Anumana, Inc.
- Website
- https://anumana.ai
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Anumana industry classification
Industry- Product category
- AI-Enabled Cardiac Diagnostics Software
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
- akta.pro secondary industries
- Cardiology Telemedicine Platforms (HLALAGAB), Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI), Electrophysiology (Heart Rhythm) (HLAKABAC)
Keywords
Where Anumana is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Anumana business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Medicare Reimbursement for ECG-AI LEF: The company's ECG-AI LEF algorithm received Medicare reimbursement as of January 2025 under the CMS Hospital Outpatient Prospective Payment System (OPPS) final rule, assigned to APC 5734. Category III CPT codes (0764T and 0765T) were assigned in 2023. This provides recurring revenue from outpatient settings for detecting low ejection fraction in adults at risk for heart failure.
- Pharmaceutical Partnership - Novartis: Multi-year strategic collaboration with Novartis Pharmaceuticals Corporation to deploy a series of AI-powered software solutions for detecting heart disease. Anumana develops algorithms while Novartis provides funding and potential co-development resources.
- Pharmaceutical Partnership - Pfizer: Multi-year agreement with Pfizer for Anumana to develop an investigational AI electrocardiogram algorithm to help identify patients who may be at risk of cardiac amyloidosis. Pfizer-backed development with potential for future licensing revenue.
- Philips ECG AI Marketplace Distribution: Partnership with Royal Philips as inaugural partner on the ECG AI Marketplace platform. Provides distribution channel to U.S. healthcare systems through Philips' established customer base, potentially generating revenue through algorithm usage fees or licensing arrangements.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Anumana product offering
Product offeringCore offering
Anumana develops and commercializes FDA-cleared AI-powered ECG analysis software (ECG-AI Platform) that detects cardiovascular conditions from standard 12-lead electrocardiograms. The portfolio includes algorithms for low ejection fraction, pulmonary hypertension, and cardiac amyloidosis, with additional algorithms in development for hyperkalemia, aortic stenosis, atrial fibrillation, and hypertrophic cardiomyopathy. The software integrates directly into hospital EHR and ECG management systems and is sold to healthcare providers, health systems, and pharmaceutical companies.
Product overview
Anumana is an AI-driven health technology company offering a portfolio of FDA-cleared ECG-AI software solutions organized around its core ECG-AI Platform. The flagship product is the ECG-AI LEF algorithm for detecting low ejection fraction (heart failure risk), which received the company's first full FDA 510(k) clearance in October 2023 and became the first AI-enabled ECG technology to receive Medicare reimbursement in January 2025. The company has since expanded its portfolio with additional FDA-cleared algorithms including ECG-AI Pulmonary Hypertension (March 2026) and ECG-AI Cardiac Amyloidosis (April 2026). The platform processes standard 12-lead ECGs using deep learning neural networks to identify subtle cardiac disease signals invisible to the human eye, with results integrated directly into healthcare institutions' EHR workflows. Anumana's technology is built on data from over 22 million patient records spanning more than 20 years and is supported by more than 100 peer-reviewed publications. The company also holds more than 300 patents protecting its AI innovations.
Differentiator
Problem solved
Functional benefit
Brands
- ECG-AI: AI-powered electrocardiogram analysis technology platform that detects cardiovascular disease from standard 12-lead ECGs
- ECG-AI LEF
- ECG-AI Pulmonary Hypertension
- ECG-AI Cardiac Amyloidosis
Products and services
- ECG-AI LEF (Low Ejection Fraction) FDA 510(k)-cleared AI algorithm that analyzes standard 12-lead ECGs to identify patients with reduced left ventricular ejection fraction (LEF), a key indicator of heart failure. Developed using approximately 2.9 million ECG-echo pairs from 676,000+ patients across diverse populations. The first AI-enabled ECG technology to receive Medicare reimbursement (January 2025).
- ECG-AI Pulmonary Hypertension FDA 510(k)-cleared AI algorithm designed to identify early signs of pulmonary hypertension (PH) using standard 12-lead ECGs. Developed using over 250,000 Mayo Clinic patient records, demonstrating 73% sensitivity and 74.4% specificity in a multi-center study of 21,066 patients across five U.S. health systems.
- ECG-AI Cardiac Amyloidosis First and only FDA-cleared AI algorithm for detecting cardiac amyloidosis using a standard 12-lead ECG. Identifies hidden cardiovascular disease from routine electrocardiograms, enabling earlier detection of AL or ATTR cardiac amyloidosis with AUC of 0.92.
- NeuTrace EP Data Biome Platform Proprietary, device-agnostic platform for holistic in-procedure data integration and real-time AI applications in cardiac electrophysiology. Covered by more than 35 pending and registered patents. Integrates patient EMR with ECG and EGM signals for improved EP procedure accuracy and safety.
- ECG-AI Hyperkalemia AI algorithm in development for non-invasive detection of elevated blood potassium (hyperkalemia) from ECG signals. Received FDA Breakthrough Device Designation. Targets bloodless potassium monitoring in patients with chronic kidney disease.
Quantifiable outcome
- ECG-AI increased heart failure detection diagnosis rates by about a third (EAGLE trial, Nature Medicine)
- +6 more outcomes
Companies that use Anumana
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Anumana technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability7 records
Feature7 records
Anumana partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and supporting.
- Royal PhilipscoreAnumana is the inaugural partner on Royal Philips ECG AI Marketplace, a centralized platform that consolidates AI-powered cardiac diagnostic tools for U.S. healthcare systems. Anumana's FDA-cleared ECG-AI LEF algorithm is the first solution available on the marketplace, enabling hospitals to integrate AI algorithms into their workflows.
- Boston ScientificsupportingBoston Scientific provided support for Anumana's expansion of its diagnostic ECG-AI technology into perioperative and acute cardiac care settings. Collaboration focused on bringing AI capabilities into additional clinical care pathways.
- AliveCorsupportingPartnership announced January 2025 for broader cardiac disease AI development. Collaboration aimed at expanding AI-enabled ECG analysis capabilities and market reach for cardiovascular disease detection applications.
- Accelerating Medicines Partnership Heart Failure (AMP HF) ProgramcoreAnumana joined the NIH/NHLBI AMP Heart Failure Program providing access to real-world data to refine AI algorithms for earlier detection of complex heart conditions. Partnership enables use of BioData Catalyst platform and longitudinal cohort data for algorithm validation.
- PfizercoreMulti-year agreement with Pfizer for development of investigational AI electrocardiogram algorithm to help identify patients at risk of cardiac amyloidosis. Pfizer provides funding and clinical development expertise while Anumana contributes AI technology development capabilities.
- NovartiscoreMulti-year strategic collaboration with Novartis Pharmaceuticals Corporation to deploy a series of AI-powered software solutions for detecting heart disease. Anumana develops and provides AI-ECG algorithms while Novartis contributes to development funding and potential commercialization support for cardiovascular AI applications.
- Framingham Heart StudysupportingNational Heart, Lung, and Blood Institute sponsored longitudinal cohort study. Anumana accessed cohort data through HeartShare/AMP HF Program for validation of ECG-AI algorithms in heart failure prediction studies.
- Multi-Ethnic Study of Atherosclerosis (MESA)supportingNHLBI-sponsored multi-center longitudinal study of subclinical cardiovascular disease. Contributed data for multi-cohort validation of ECG-AI algorithms through HeartShare/AMP HF Program.
- Mayo CliniccoreMayo Clinic is the co-founding partner of Anumana and primary source of clinical data for algorithm development. Mayo Clinic Platform provides access to de-identified patient records spanning over 22 million records and 20 years of data. Mayo Clinic physicians serve as advisors and investigators for clinical validation studies.
- nferencecorenference is the co-founding partner of Anumana along with Mayo Clinic. nference provides its nSights real-world evidence generation platform and AI/ML technical capabilities. nference acquired rights to NeuTrace Data Biome platform for uses outside of cardiovascular field as part of the NeuTrace acquisition.
Scale indicators13 records
Recent moves8 records
Expansion highlights7 records
Anumana competitors and assessment
Company assessmentDirect peers
- Eko Health: Eko Health builds AI-enabled cardiac auscultation and ECG analysis tools for clinicians and health systems. Eko's AI cardiac detection platform overlaps directly with Anumana's ECG-AI franchise in applying deep learning to cardiac signal interpretation within hospital workflows.
- AliveCor: AliveCor (KardiaMobile, KardiaStation) is an AI-ECG platform with FDA-cleared personal and clinical ECG devices. Anumana is a known collaboration partner of AliveCor (Jan 2025) and both companies operate AI-ECG algorithms for cardiovascular detection, although AliveCor is more consumer-proximate and Anumana is more hospital-anchored.
- Ultromics: Ultromics develops AI-ECG and AI-echocardiography algorithms for cardiovascular disease detection, including heart failure with preserved ejection fraction (HFpEF). Anumana and Ultromics both apply deep learning to cardiac signals for early-disease detection, serving similar healthcare-system and pharma customers with FDA-cleared SaMD.
- Cardio Diagnostics: Cardio Diagnostics develops AI-driven epigenomic and ECG-based cardiovascular diagnostics. Its focus on AI-ECG for cardiovascular disease screening and risk stratification parallels Anumana's ECG-AI product line.
Broad incumbents
- HeartFlow: HeartFlow provides AI-enabled cardiac CT-FFR analysis for coronary disease. Although HeartFlow focuses on imaging rather than ECG, both companies sit in the AI-driven cardiovascular diagnostics category serving hospital systems and operating under similar CPT/reimbursement frameworks.
- iRhythm Technologies: iRhythm Technologies (Zio long-term cardiac monitoring patch) is a publicly traded cardiac monitoring company. It overlaps with Anumana in AI-enabled arrhythmia and cardiovascular disease detection but focuses on ambulatory patch monitoring rather than 12-lead ECG analysis.
- Philips (Royal Philips): Royal Philips is both a strategic partner (Anumana is inaugural partner on the Philips ECG AI Marketplace) and a broad incumbent in cardiology informatics (ECG management systems, cardiac imaging, AI). The relationship signals both an opportunity and a competitive exposure for Anumana.
- GE HealthCare: GE HealthCare is a major incumbent in cardiac diagnostics (ECG, imaging, monitoring) and is investing in AI cardiology. As a broad medtech incumbent with established hospital relationships, it represents both a competitive threat and a potential exit partner for Anumana.
Emerging players
- Caption Health: Caption Health develops AI guidance for cardiac ultrasound (echocardiography). It overlaps with Anumana at the intersection of AI-driven cardiac diagnostics and clinician workflow, though focused on imaging rather than ECG signal analysis.
- Cleerly: Cleerly applies AI to cardiac CT angiography for plaque analysis. Like Anumana, it offers AI diagnostic tools to healthcare systems for early cardiovascular disease detection, addressing a similar need but via imaging rather than ECG.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Anumana social profiles
Digital presenceAnumana compliance and trust
Trust signalCompliance6 records
Anumana financial estimates
Financial estimateRevenue estimate
Valuation estimate
Anumana leadership team
Management profileNumber of profiles
Profiles8 records
Anumana subsidiaries and ownership
Company hierarchySubsidiaries1 record
Anumana funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Anumana M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Anumana
What does Anumana do?
Anumana develops and commercializes FDA-cleared AI-powered ECG analysis software (ECG-AI Platform) that detects cardiovascular conditions from standard 12-lead electrocardiograms. The portfolio includes algorithms for low ejection fraction, pulmonary hypertension, and cardiac amyloidosis, with additional algorithms in development for hyperkalemia, aortic stenosis, atrial fibrillation, and hypertrophic cardiomyopathy. The software integrates directly into hospital EHR and ECG management systems and is sold to healthcare providers, health systems, and pharmaceutical companies.
Is Anumana a public or private company?
Anumana is a private company. It is classified as venture growth investor backed and is currently operating.
When was Anumana founded?
Anumana was founded in 2021. It employs 101 to 250 people.
Where is Anumana based?
Anumana is headquartered in Cambridge, United States, in the North America region.
How does Anumana make money?
Four revenue lines are on record. Medicare Reimbursement for ECG-AI LEF is the primary driver. The others are pharmaceutical Partnership - Novartis, pharmaceutical Partnership - Pfizer and philips ECG AI Marketplace Distribution.
Who are Anumana's main competitors?
Direct peers on record are Eko Health, AliveCor, Ultromics and Cardio Diagnostics. Broad incumbents are HeartFlow, iRhythm Technologies, Philips (Royal Philips) and GE HealthCare. Emerging players are Caption Health and Cleerly.
Does Anumana have an API?
No public API is recorded for Anumana.
What industry is Anumana in?
Anumana's product category is AI-Enabled Cardiac Diagnostics Software. Its primary akta.pro industry code is HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity), with a secondary code of HLALAGAB, Cardiology Telemedicine Platforms. Its NAICS code is 334510 and its SIC code is 3845.